The Main Pharmaceutical Inspectorate has ordered an immediate nationwide freeze on a specific batch of the hospital-administered drug Viantan following the discovery of a large glass fragment inside a vial.
Immediate Safety Halt
The Main Pharmaceutical Inspectorate (GIF) has suspended the distribution of one batch of Viantan, a medication used in hospital settings. The decision was prompted by a quality defect report after a large piece of glass was discovered inside a vial during the preparation of the drug for infusion.
The decision carries an immediate enforcement clause, requiring hospitals to secure the product and halt its use. Because the investigation is ongoing, authorities have not yet ruled out the possibility that other vials from the same production series could be compromised.
Discovery and Potential Cause
The issue was first identified by a hospital pharmacy in Poznan while staff were preparing the medication for a patient. The vial in question has been forwarded to the manufacturer for analysis.
Preliminary findings suggest the glass fragment may have originated from the vial fracturing during the lyophilization process, a technical method used to dehydrate the drug. While the manufacturer claims no other similar complaints have been recorded for this batch, a full risk assessment is still underway.
Clinical Risks and Standards
Viantan is an intravenous infusion drug used for both adults and children over the age of 11 to address vitamin deficiencies. Intravenous medications are held to strict safety standards, as they must be practically free of particles to avoid serious health risks.
The manufacturer argued that the glass fragment would likely not pass through an infusion system and that medical staff are required to inspect solutions before administration. However, the GIF deemed these explanations insufficient given the lack of a conclusive cause for the contamination.
Guidance for Hospitals and Patients
The current decision is a temporary precautionary measure to protect public health while the investigation proceeds. It is distinct from a full market recall, though it effectively stops the drug from being used.
Patients awaiting treatment are advised that this does not necessarily mean their therapy will be interrupted, as hospitals frequently maintain alternative stocks or similar medications. Hospitals are currently following emergency protocols to secure batch number 82947TB24 and seek suitable replacements.
